Funding for new RCT in migraine

The Nordic Chronic Migraine Trial of CGRP monoclonal antibody and onabotulinumtoxin A dual therapy – a randomized-controlled double-blind trial (NorMig) – a new RCT led by Aamodt was awarded 9 mill NOK from the South Eastern Health Authority in December 2023

Individuell-innstillingsliste-tematisk-apen.pdf

 

 
Page visits: 151